PT  - JOURNAL ARTICLE
AU  - Siegerink, Bob
AU  - Weber, Joachim
AU  - Ahmadi, Michael
AU  - Eckardt, Kai-Uwe
AU  - Edelmann, Frank
AU  - Endres, Matthias
AU  - Gerhardt, Holger
AU  - Haubold, Kathrin
AU  - Hübner, Norbert
AU  - Landmesser, Ulf
AU  - Leistner, David
AU  - Mai, Knut
AU  - Müller, Dominik N
AU  - Pieske, Burkert
AU  - Rauch, Geraldine
AU  - Schmidt, Sein
AU  - Schmidt-Ott, Kai
AU  - Schulz-Menger, Jeanette
AU  - Spranger, Joachim
AU  - Pischon, Tobias
TI  - Disease overarching mechanisms that explain and predict outcome of patients with high cardiovascular risk: rationale and design of the Berlin Long-term Observation of Vascular Events (BeLOVE) study
AID  - 10.1101/19000380
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19000380
4099  - http://medrxiv.org/content/early/2019/06/25/19000380.short
4100  - http://medrxiv.org/content/early/2019/06/25/19000380.full
AB  - Background: Cardiovascular disease (CVD) is the leading cause of premature death worldwide. Effective and individualized treatment requires exact knowledge about both risk factors and risk estimation. Most evidence for risk prediction currently comes from population-based studies on first incident cardiovascular events. In contrast, little is known about the relevance of risk factors for the outcome of patients with established CVD or those who are at high risk of CVD, including patients with type 2 diabetes. In addition, most studies focus on individual diseases, whereas less is known about disease overarching risk factors and cross-over risk. Aim: The aim of BeLOVE is to improve short- and long-term prediction and mechanistic understanding of cardiovascular disease progression and outcomes in very high-risk patients, both in the acute as well as in the chronic phase, in order to provide the basis for improved, individualized management. Study design: BeLOVE is an observational prospective cohort study of patients of both sexes aged >18 in selected Berlin hospitals, who have a high risk of future cardiovascular events, including patients with a history of acute coronary syndrome (ACS), acute stroke (AS), acute heart failure (AHF), acute kidney injury (AKI) or type 2 diabetes with manifest target-organ damage. BeLOVE includes 2 subcohorts: The acute subcohort includes 6500 patients with ACS, AS, AHF, or AKI within 2-8 days after their qualifying event, who undergo a structured interview about medical history as well as blood sample collection. The chronic subcohort includes 6000 patients with ACS, AS, AHF, or AKI 90 days after event, and patients with type 2 diabetes (T2DM) and target-organ damage. These patients undergo a 6-8 hour deep phenotyping program, including detailed clinical phenotyping from a cardiological, neurological and metabolic perspective, questionnaires including patient-reported outcome measures (PROMs)as well as magnetic resonance imaging. Several biological samples are collected (i.e. blood, urine, saliva, stool) with blood samples collected in a fasting state, as well as after a metabolic challenge (either nutritional or cardiopulmonary exercise stress test). Ascertainment of major adverse cardiovascular events (MACE) will be performed in all patients using a combination of active and passive follow-up procedures, such as on-site visits (if applicable), telephone interviews, review of medical charts, and links to local health authorities. Additional phenotyping visits are planned at 2, 5 and 10 years after inclusion into the chronic subcohort. Future perspective: BeLOVE provides a unique opportunity to study both the short- and long-term disease course of patients at high cardiovascular risk through innovative and extensive deep phenotyping. Moreover, the unique study design provides opportunities for acute and post-acute inclusion and allows us to derive two non-nested yet overlapping sub-cohorts, tailored for upcoming research questions. Thereby, we aim to study disease-overarching research questions, to understand crossover risk, and to find similarities and differences between clinical phenotypes of patients at high cardiovascular risk.Competing Interest Statementto be providedClinical TrialGerman Clinical Trials Registry DRKS00016852Funding StatementThe costs related to study management, data collection, and biobanking are funded by the Berlin Institute of Health, which was founded by the Charit? ? Universit?tsmedizin Berlin and Max Delbr?ck Center for Molecular Medicine in the Helmholtz Association (MDC). Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.NANA